Carfilzomib

Generic Name: Carfilzomib

Brand Names: Kyprolis

Drug Type: Small Molecule

Chemical Formula: C_₄₀H_₅₇N_₅O_₇

CAS Number: 868540-17-4

Unique Ingredient Identifier: 72X6E3J5AR

Background: Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.

Indication: Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.

Associated Conditions: Relapsed/Refractory Multiple Myeloma (RRMM)

Associated Therapies: -

Clinical Trials

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Phase 1

Suspended

Conditions: Metastatic Breast Carcinoma
Recurrent Breast Carcinoma
Recurrent Hodgkin Lymphoma
Refractory Hodgkin Lymphoma
Breast Adenocarcinoma
Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Refractory Nodal Marginal Zone Lymphoma
Recurrent Mycosis Fungoides
Recurrent Non-Hodgkin Lymphoma
Refractory Non-Hodgkin Lymphoma

Interventions: Drug: Belinostat
Drug: Carfilzomib
Drug: Copanlisib Hydrochloride
Biological: Daratumumab
Drug: Fludeoxyglucose F-18
Drug: Gemcitabine Hydrochloride
Other: Laboratory Biomarker Analysis
Biological: Nivolumab
Biological: Obinutuzumab
Biological: Pembrolizumab
Procedure: Positron Emission Tomography
Biological: Rituximab
Drug: Romidepsin
Other: Saline
Biological: Trastuzumab

First Posted Date: 2018-02-14

Last Posted Date: 2023-09-13

Lead Sponsor: Mayo Clinic

Target Recruit Count: 39

Registration Number: NCT03432741

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy

Phase 4

Completed

Conditions: Relapsed and/or Refractory Multiple Myeloma

Interventions: Drug: Ixazomib
Drug: Bortezomib
Drug: Carfilzomib
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2018-01-31

Last Posted Date: 2022-09-27

Lead Sponsor: Takeda

Target Recruit Count: 45

Registration Number: NCT03416374

Locations: 🇯🇵
Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan
🇯🇵
Kyorin University Hospital, Mitaka, Tokyo, Japan
🇯🇵
Nippon Medical School Hospital, Bunkyo-ku, Tokyo, Japan

and more 20 locations

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Daratumumab
Drug: Bortezomib
Drug: Lenalidomide
Drug: Melphalan
Drug: Carfilzomib
Drug: Dexamethasone
Drug: Prednisone

First Posted Date: 2018-01-26

Last Posted Date: 2024-05-24

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 265

Registration Number: NCT03412565

Locations: 🇺🇸
Cancer Center of Central Connecticut - Southington, Southington, Connecticut, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Avera Medical Group - Oncology & Hematology, Sioux Falls, South Dakota, United States

and more 60 locations

Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Dexamethasone
Drug: cyclophosphamide

First Posted Date: 2017-11-08

Last Posted Date: 2022-09-07

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 199

Registration Number: NCT03336073

Locations: 🇪🇸
Hospital de León, León, Spain
🇪🇸
H. Ramón y Cajal, Madrid, Spain
🇪🇸
Hospital Universitario de Santiago, Santiago De Compostela, Spain

and more 21 locations

Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.

Phase 2

Active, not recruiting

Conditions: Myeloma

Interventions: Drug: Carfilzomib
Drug: Lenalidomide
Device: PET-CT
Drug: Dexamethasone

First Posted Date: 2017-10-19

Last Posted Date: 2023-05-06

Lead Sponsor: Oslo University Hospital

Target Recruit Count: 53

Registration Number: NCT03314636

Locations: 🇸🇪
Skåne University Hospital, Lund, Sweden
🇩🇰
Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
🇩🇰
Odense University Hospital, Odense, Denmark

and more 1 locations

A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: daratumumab
Drug: carfilzomib
Drug: lenalidomide
Drug: dexamethasone

First Posted Date: 2017-09-25

Last Posted Date: 2024-07-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 75

Registration Number: NCT03290950

Locations: 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

and more 4 locations

Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant

Phase 2

Active, not recruiting

Conditions: Smoldering Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Lenalidomide
Drug: Daratumumab
Drug: Dexamethasone

First Posted Date: 2017-09-20

Last Posted Date: 2023-12-12

Lead Sponsor: International Myeloma Foundation

Target Recruit Count: 87

Registration Number: NCT03289299

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States

and more 7 locations

Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients

Phase 3

Active, not recruiting

Conditions: Plasma Cell Myeloma

Interventions: Drug: isatuximab SAR650984
Drug: carfilzomib
Drug: dexamethasone

First Posted Date: 2017-09-07

Last Posted Date: 2024-12-10

Lead Sponsor: Sanofi

Target Recruit Count: 302

Registration Number: NCT03275285

Locations: 🇺🇸
UCSF MS Center Site Number : 8400002, San Francisco, California, United States
🇺🇸
Spartanburg Medical Center Site Number : 8400003, Spartanburg, South Carolina, United States
🇦🇺
Investigational Site Number : 0360005, Blacktown, New South Wales, Australia

and more 67 locations

Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma

Phase 2

Terminated

Conditions: Marginal Zone Lymphoma
Recurrent Marginal Zone Lymphoma
Recurrent Waldenstrom Macroglobulinemia
Refractory Marginal Zone Lymphoma
Refractory Waldenstrom Macroglobulinemia
Waldenstrom Macroglobulinemia

Interventions: Drug: Carfilzomib
Other: Laboratory Biomarker Analysis
Biological: Rituximab

First Posted Date: 2017-08-31

Last Posted Date: 2020-01-18

Lead Sponsor: University of Washington

Target Recruit Count: 4

Registration Number: NCT03269552

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Phase 2

Terminated

Conditions: Refractory Plasma Cell Myeloma
Recurrent Plasma Cell Myeloma

Interventions: Drug: Carfilzomib
Other: Chemosensitivity Assay
Drug: Dexamethasone
Other: Laboratory Biomarker Analysis
Drug: Panobinostat

First Posted Date: 2017-08-21

Last Posted Date: 2022-05-09

Lead Sponsor: University of Washington

Target Recruit Count: 9

Registration Number: NCT03256045

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy